Literature DB >> 18998146

[The basics of refractive lens exchange].

T Kohnen1, O K Klaproth.   

Abstract

Removal of the crystalline lens and its replacement by an intraocular lens (IOL) is known as refractive lens exchange (RLE). RLE is performed to correct high ametropia or aniseikonia. Crystalline lens removal always leads to a complete loss of accommodation; therefore, RLE should mainly be used for patients with beginning or existing presbyopia. RLE patients usually have a good best-corrected visual acuity, which is the default value for the postoperative uncorrected visual acuity. To reach this goal, microincisional and astigmatism-neutral implantation techniques as well as special IOL optic designs are available. These optic designs offer each patient individualized best visual performance. In spite of the high requirements for postoperative optical quality, RLE can lead to an effective, safe, predictable, and stable outcome with a low risk of complications.

Entities:  

Mesh:

Year:  2008        PMID: 18998146     DOI: 10.1007/s00347-008-1827-7

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  35 in total

1.  Early rotational stability of the longer Staar toric intraocular lens: fifty consecutive cases.

Authors:  David F Chang
Journal:  J Cataract Refract Surg       Date:  2003-05       Impact factor: 3.351

2.  Comparison of two acrylic intraocular lenses with different haptic designs in patients with combined phacoemulsification and pars plana vitrectomy.

Authors:  A Mingels; J Koch; A Lommatzsch; D Pauleikhoff; A Heiligenhaus
Journal:  Eye (Lond)       Date:  2006-06-09       Impact factor: 3.775

3.  Visual performance of patients with bilateral vs combination Crystalens, ReZoom, and ReSTOR intraocular lens implants.

Authors:  Jay S Pepose; Mujtaba A Qazi; James Davies; John F Doane; James C Loden; Varunan Sivalingham; Ashraf M Mahmoud
Journal:  Am J Ophthalmol       Date:  2007-07-25       Impact factor: 5.258

Review 4.  [Use of multifocal intraocular lenses and criteria for patient selection].

Authors:  T Kohnen; D Kook; G U Auffarth; V Derhartunian
Journal:  Ophthalmologe       Date:  2008-06       Impact factor: 1.059

5.  Clear lens extraction to correct hyperopia.

Authors:  W A Lyle; G J Jin
Journal:  J Cataract Refract Surg       Date:  1997-09       Impact factor: 3.351

Review 6.  [IOL calculation for high ametropia].

Authors:  W Haigis
Journal:  Ophthalmologe       Date:  2008-11       Impact factor: 1.059

7.  Phacoemulsification of the crystalline lens and implantation of an intraocular lens for the correction of moderate and high myopia: four-year follow-up.

Authors:  José L Güell; Andrés F Rodriguez-Arenas; Oscar Gris; Francoise Malecaze; Fortino Velasco
Journal:  J Cataract Refract Surg       Date:  2003-01       Impact factor: 3.351

8.  Visual results following implantation of a refractive multifocal IOL in one eye and a diffractive multifocal IOL in the contralateral eye.

Authors:  Frank Joseph Goes
Journal:  J Refract Surg       Date:  2008-03       Impact factor: 3.573

9.  Refractive lens exchange versus iris-claw Artisan phakic intraocular lens for hyperopia.

Authors:  Mihai Pop; Yves Payette
Journal:  J Refract Surg       Date:  2004 Jan-Feb       Impact factor: 3.573

Review 10.  [Toric intraocular lenses and correction of astigmatism].

Authors:  Arne Viestenz; S Walter; Anja Viestenz; W Behrens-Baumann; A Langenbucher
Journal:  Ophthalmologe       Date:  2007-07       Impact factor: 1.174

View more
  2 in total

1.  Refractive lens exchange with distance-dominant diffractive bifocal intraocular lens implantation.

Authors:  José F Alfonso; Luis Fernández-Vega; Susana Ortí; Robert Montés-Micó
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-03-16       Impact factor: 3.117

2.  [Evaluation and quality assurance of refractive surgery procedures by the German Ophthalmological Society and the Professional Association of German Ophthalmologists. Status: May 2011].

Authors:  T Kohnen; T Neuhann; M Knorz
Journal:  Ophthalmologe       Date:  2011-09       Impact factor: 1.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.